Sarepta’s Elevidys: FDA Lifts Pause, Shares Surge

Sarepta’s Elevidys gets FDA green light to resume, sending shares soaring. What does this mean for the future of gene...

29/07/2025

2 views

Sarepta Stock Crashes After Europe Rejects Gene Therapy

Sarepta Therapeutics faces a brutal stock crash after Europe rejects its gene therapy drug Elevidys. What does this mean for...

25/07/2025

2 views

Sarepta halts Elevidys shipments after tragic patient deaths. What does this mean for biotech trust and innovation? Click to uncover...

22/07/2025

3 views

Sarepta’s Elevidys faces FDA scrutiny after patient deaths spark safety concerns. Will the gene therapy stay on the market? Click...

21/07/2025

1 views

Genomics is reshaping medicine and markets. Ready to invest in the future of healthcare? Discover the best biotech stocks to...

25/04/2025

0 views

Roche’s $50B US investment is shaking up pharma with new jobs and cutting-edge facilities. But what’s driving this bold move?...

22/04/2025

0 views